Gene Vector’s BL-4040 prevents apoptosis of kidney cells after acute injury.
BioLineRx signed a worldwide, exclusive license agreement with Gene Vector Technologies for the development and commercialization of BL-4040, a drug for the treatment of acute kidney injury (AKI).
BL-4040 is a genetically engineered version of the major capsid protein VP1, derived from the outer protein shell of the virus SV40. By boosting the natural stress response and survival pathways of kidney cells, BL-4040 may prevent apoptosis of kidney cells following AKI, the companies explain.
“BL-4040 is extremely effective in mice, relatively simple to produce, and nontoxic even at very high doses,” says Morris C. Laster, M.D., CEO of BioLineRx. “We believe that BL-4040 offers the potential for a highly effective and safe therapy that taps into the natural defense systems of the body.”